Edwards Lifesciences Co. (NYSE:EW) Shares Sold by Swiss National Bank

Swiss National Bank cut its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 4.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,701,800 shares of the medical research company's stock after selling 86,800 shares during the period. Swiss National Bank owned about 0.29% of Edwards Lifesciences worth $125,984,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in EW. FSA Wealth Management LLC purchased a new position in Edwards Lifesciences in the third quarter valued at $30,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Edwards Lifesciences in the 4th quarter valued at about $30,000. Prospera Private Wealth LLC acquired a new stake in Edwards Lifesciences in the third quarter valued at approximately $32,000. Avior Wealth Management LLC grew its holdings in Edwards Lifesciences by 138.7% during the 3rd quarter. Avior Wealth Management LLC now owns 530 shares of the medical research company's stock worth $35,000 after acquiring an additional 308 shares in the last quarter. Finally, Roble Belko & Company Inc acquired a new stake in shares of Edwards Lifesciences in the 4th quarter valued at $46,000. Institutional investors and hedge funds own 79.46% of the company's stock.

Edwards Lifesciences Stock Performance

Shares of Edwards Lifesciences stock traded down $0.33 on Tuesday, reaching $70.31. 3,702,921 shares of the stock were exchanged, compared to its average volume of 4,582,000. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $41.33 billion, a PE ratio of 10.09, a PEG ratio of 4.82 and a beta of 1.12. Edwards Lifesciences Co. has a 1-year low of $58.93 and a 1-year high of $96.12. The business has a fifty day moving average price of $71.68 and a two-hundred day moving average price of $70.34.

Remove Ads

Edwards Lifesciences (NYSE:EW - Get Free Report) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.59 EPS for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. As a group, research analysts anticipate that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

EW has been the subject of several analyst reports. Evercore ISI lowered their price objective on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a research report on Wednesday, February 12th. Citigroup boosted their price objective on shares of Edwards Lifesciences from $81.00 to $83.00 and gave the stock a "buy" rating in a research report on Wednesday, December 11th. Stifel Nicolaus upgraded shares of Edwards Lifesciences from a "hold" rating to a "buy" rating and upped their target price for the company from $75.00 to $90.00 in a report on Thursday, January 30th. Truist Financial reiterated a "hold" rating and set a $78.00 price target (up from $70.00) on shares of Edwards Lifesciences in a research note on Thursday, December 5th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $85.00 price objective on shares of Edwards Lifesciences in a research note on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, fourteen have assigned a hold rating and twelve have assigned a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $79.95.

Insider Activity at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 400 shares of Edwards Lifesciences stock in a transaction on Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the completion of the transaction, the vice president now directly owns 22,588 shares of the company's stock, valued at approximately $1,569,414.24. The trade was a 1.74 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CFO Scott B. Ullem sold 11,250 shares of the business's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.76, for a total value of $852,300.00. Following the sale, the chief financial officer now owns 30,561 shares in the company, valued at approximately $2,315,301.36. The trade was a 26.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 51,303 shares of company stock worth $3,715,776 over the last 90 days. Company insiders own 1.29% of the company's stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.